GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January29, 2019, the Board of Directors of Genomic Health,Inc. (the “Company”) elected Barry P. Flannelly to serve as a member of the Board of Directors of the Company effective on April16, 2019. In addition, Dr.Flannelly will serve on the Audit Committee of the Board of Directors.
Dr.Flannelly has served as Executive Vice President and General Manager US of Incyte Corporation, a biopharmaceutical company, since June2015 and served as Executive Vice President, Business Development and Strategic Planning of Incyte from August2014 to June2015. Dr.Flannelly served as Chief Executive Officer of OSS Healthcare Inc., a biotechnology company, from August2013 to July2014, Vice President, Global Product Strategy and Commercial Planning of Nektar Therapeutics, a biopharmaceutical company, from April2011 until April2013, and Senior Vice President, Commercial, of Onyx Pharmaceuticals,Inc., a biopharmaceutical company, from August2008 until January2011. Prior thereto, Dr.Flannelly held key positions at biopharmaceutical and pharmaceutical companies such as Abraxis BioScience,Inc. and Novartis. Dr.Flannelly holds a B.S. in Pharmacy from Massachusetts College of Pharmacy, an M.B.A. from the University of Baltimore, and a Pharm.D. from the University of Maryland, School of Pharmacy.
As a non-employee director of the Company, Dr.Flannelly will be entitled to the same cash and equity compensation paid by the Company to each of its non-employee directors, as described in the Company’s proxy statement for its 2018 Annual Meeting of Stockholders filed on April27, 2018.
About GENOMIC HEALTH,INC. (NASDAQ:GHDX)
Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.
